← Markets

Agilon Health, Inc.

AGL · NYSE

Market closed$129.84$8.62 (+7.11%)After hours $132.43 · +1.99%

Key statistics

Previous close$121.22
Open$118.87
Day high$133.04
Day low$117.82
52-week high$133.04
52-week low$7.48
Market cap2.17B
Volume344.83K
Average volume416.51K
P/E ratio-12.70
Forward P/E—
EPS-10.22
Dividend yield0.00%

Market context

Why it moved

Agilon Health (AGL) surged sharply higher, driven by strong momentum following the company's announcement that its REACH Accountable Care Organizations generated $229 million in gross savings with high quality scores, reinforcing investor confidence in the sustainability of its value-based care model and contributing to an extraordinary year-to-date gain that has made it one of the top-performing stocks of 2026.

StockinvestSimplywallSimplywallInstagramRobinhood

What is happening

Recent company-specific developments and publisher coverage.

July 18, 2026Agilon Health surged to a fresh 52-week high, riding a powerful sector tailwind from UnitedHealth Group's blockbuster Q2 2026 earnings beat — which saw adjusted EPS of $6.38 (vs. ~$4.85 consensus) and a 270 basis-point improvement in its medical care ratio — signaling that Medicare Advantage cost trends may be improving broadly. Wells Fargo reiterated its Buy rating with a $141 price target on AGL, while the AI-driven value-based care narrative continues to attract momentum investors, with the stock now up roughly 130% over the past year under new CEO Tim O'Rourke, appointed in May.

7.111

July 17, 2026Agilon Health shares fell nearly 2.5% in a volatile session — trading between $116.19 and $130.16 — and continued declining in after-hours, even as the broader sector rallied sharply on UnitedHealth Group's blowout Q2 earnings beat. UNH surged over 4% after reporting a medical cost ratio of 86.7% (vs. 88.47% expected) and raising full-year guidance, lifting managed care sentiment broadly. However, AGL faces lingering valuation tension: the stock hit a 52-week high near $126 just the day prior and is up ~612% year-to-date, trading well above most analyst price targets. Wells Fargo recently raised its target to $141 with a Buy rating, while others maintain Hold with targets as low as $67–$92, reflecting uncertainty around the stock's premium valuation despite strong recent momentum fueled by the AI care narrative and new CEO Tim O'Rourke's value-based care mandate.

-2.47

July 16, 2026Agilon Health shares gained over 1%, touching a fresh 52-week high of $126.03, supported by a major analyst upgrade from Wells Fargo, which raised its price target to $141 from $72 while maintaining a Buy rating. The bullish call builds on Agilon's strong momentum since its Q1 beat and guidance raise in May, when multiple analysts including Jefferies and Deutsche Bank also upgraded the stock. The broader healthcare sector provided additional tailwinds, with UBS flagging the space as a key allocation focus amid improving earnings revisions, while peer health insurer Elevance Health posted strong Q2 results.

1.3702

July 14, 2026Agilon Health edged higher, outperforming broader healthcare peers as investors digested a fresh analyst catalyst: Wells Fargo raised its price target to $141 (from $72) while maintaining an Overweight rating. The upgrade follows strong Q1 momentum — including a revenue beat and raised FY2026 guidance — and a July 10 disclosure showing Agilon's ACO REACH program generated $229M in 2024 gross savings. The broader healthcare sector faces Q2 earnings headwinds, with XLV under modest pressure ahead of key reports from J&J and UnitedHealth this week.

0.8707

July 11, 2026Agilon Health edged lower, with shares closing modestly down despite a positive operational update showing its eight Medicare REACH ACOs generated $229M in gross savings at a 13.6% rate with a 96% quality score in 2024. Barclays maintained a Hold rating with an $81 price target — well below current trading levels — tempering enthusiasm even as the stock has surged roughly 55% year-to-date following a strong Q1 beat and guidance raise in May that prompted Buy upgrades from Jefferies and Deutsche Bank.

-0.7089

July 9, 2026Agilon Health shares rose nearly 3.5% during the regular session and extended gains in after-hours trading, advancing an additional ~2% to around $118, significantly outperforming the broader healthcare sector (XLV nearly flat in extended hours) and the S&P 500. The move comes as healthcare stocks broadly have been among the market's top performers in recent weeks, with XLV up 6.6% in June alone, while investors rotate away from tech and AI names amid geopolitical uncertainty tied to the U.S.-Iran conflict. Agilon also announced its Q2 2026 earnings call is set for August 5, keeping investor attention focused on the value-based care company's upcoming results.

3.4708

July 9, 2026Agilon Health shares rose sharply, bucking a broadly risk-off session driven by Trump's declaration that the U.S.-Iran ceasefire was 'over,' which sent oil prices surging and weighed on major indices. The healthcare sector led the market as a defensive rotation accelerated—XLV notched its second consecutive week of outperformance—with 91% of S&P 500 healthcare stocks posting relative strength. Adding a company-specific catalyst, Agilon announced it will report Q2 2026 results on August 5, while rival Pearl Health's $110M fundraise underscored robust investor appetite for Medicare-focused, AI-driven care models.

4.0197

July 7, 2026Agilon Health closed essentially unchanged after announcing it will report second-quarter 2026 results on August 5, with an earnings call to follow. Investor attention remains focused on the company's strong Q1 momentum — AGL surged over 50% in May after posting a Q1 revenue beat of $1.42B, raising FY2026 revenue guidance to $5.68B–$5.81B, and receiving a Jefferies upgrade to Buy with a $48 price target. The stock has gained roughly 55% year-to-date, and the healthcare sector has been the market's standout performer amid a rotation away from tech, with XLV near its 52-week high.

-0.1208

Simply Wall Street · July 18, 2026agilon Health (AGL) Stock Looks Undervalued On Sales But Rich After A 7x RunSimply Wall Street · July 11, 2026The Bull Case For agilon health (AGL) Could Change Following Strong 2024 REACH ACO Savings And QualityBusiness Wire · July 10, 2026agilon health Reports ACO REACH Model Results for 2024 Performance YearBusiness Wire · May 6, 2026agilon health Reports First Quarter 2026 Results
Benzinga · July 13, 2026Wells Fargo Maintains Overweight on Agilon Health, Raises Price Target to $141
Benzinga · May 26, 2026Barclays Upgrades Agilon Health to Equal-Weight, Announces $81 Price Target
Benzinga · May 21, 2026Benchmark Maintains Buy on Agilon Health, Lowers Price Target to $95
Benzinga · May 11, 2026TD Cowen Maintains Hold on Agilon Health, Raises Price Target to $55
Benzinga · May 8, 2026Wells Fargo Maintains Overweight on Agilon Health, Raises Price Target to $72
Benzinga · May 7, 2026Evercore ISI Group Maintains In-Line on Agilon Health, Raises Price Target to $32
Benzinga · May 7, 2026Jefferies Upgrades Agilon Health to Buy, Raises Price Target to $48
Benzinga · May 7, 2026Baird Maintains Neutral on Agilon Health, Raises Price Target to $35

Peers

S&P 500SPX · $7,457.69-1.01%Alignment Healthcare, Inc.ALHC · $20.60+2.85%Privia Health Group, Inc.PRVA · $26.90-1.18%Evolent Health, Inc.EVH · $5.81+2.47%Clover Health Investments, Corp.CLOV · $4.62+5.00%Oscar Health, Inc.OSCR · $29.10+0.83%HCA Healthcare, Inc.HCA · $371.18-3.77%Tenet Healthcare CorporationTHC · $194.91-2.15%DaVita Inc.DVA · $236.97+1.26%Aveanna Healthcare Holdings Inc.AVAH · $9.69-2.12%The Pennant Group, Inc.PNTG · $41.95+0.58%AMN Healthcare Services, Inc.AMN · $35.00+2.28%